"The updated OST-HER2 data presented at MIB Factor that showed EFS data statistically ... comprehensive plans for the finalization of this data package to the US Food & Drug Administration’s ("FDA").

HER2-positive breast cancer carries more HER2 protein on the tumor surface than normal cells. That protein acts like a stuck accelerator pedal, making the cancer spread faster than most hormone ...

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission. Tukysa ...

Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein HER2. The decision makes the infused ...

Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer — Response rates reached 41-47% with different approaches in rare disease by Ian Ingram , Managing Editor, MedPage Today June 3 ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2 ...

HER2 is a protein that can cause a more aggressive form of breast cancer. ... This includes drugs that specifically work to kill or stop the growth of cancer-causing cells without damaging healthy ...

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC ...

An investigational antibody-drug conjugate proved active and safe for patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC), a phase II trial from China showed.

A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.